ConductScience.org, home

Paper39196380

Recent advances in CD5+ diffuse large B-cell lymphoma.

Yue N and 5 others. Ann Hematol, 2024. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Recent advances in CD5+ diffuse large B-cell lymphoma. Papers, record 39196380. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39196380

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Recent advances in CD5+ diffuse large B-cell lymphoma.
PubMed
Journal
Ann Hematol
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
1.0, provisional
iCite
Revised in PubMed
2024-11-04
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yue NNingning
2Jin QQiqi
3Li CCuicui
4Zhang LLitian
5Cao JJiajia
6Wu CChongyang

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Lymphoma, Large B-Cell, DiffuseMajor topic
CD5 AntigensMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
DoxorubicinMajor topic
Humans
Cyclophosphamide
Rituximab
Vincristine
Prednisone
Female
Etoposide
Male
Prognosis

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
8226010026National Natural Science Foundation of ChinaPubMed
22JR11RA053Scientific Research Project of Gansu ProvincePubMed
201710The "CuiYing postgraduate tutor" training program of Lanzhou University Second HospitalPubMed

Source PubMed

Download CSV of grants

References89

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123375551Diffuse large B-cell lymphoma.Crit Rev Oncol Hematol2013https://conductscience.org/library/papers/23375551PubMed
235167823All roads lead to targeted diffuse large B-cell lymphoma approaches.Cancer Cell2022https://conductscience.org/library/papers/35167823PubMed
325499448Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.Blood2015https://conductscience.org/library/papers/25499448PubMed
418556402De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.Haematologica2008https://conductscience.org/library/papers/18556402PubMed
511806981De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.Blood2002https://conductscience.org/library/papers/11806981PubMed
626369546CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma.Virchows Arch2015https://conductscience.org/library/papers/26369546PubMed
718573805CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.Ann Oncol2008https://conductscience.org/library/papers/18573805PubMed
811061284Genomic organization of the human CD5 gene.Immunogenetics2000https://conductscience.org/library/papers/11061284PubMed
910379049CD5 expression in human B-cell populations.Immunol Today1999https://conductscience.org/library/papers/10379049PubMed
1030581443CD5, an Undercover Regulator of TCR Signaling.Front Immunol2018https://conductscience.org/library/papers/30581443PubMed
113264319Monoreactive high affinity and polyreactive low affinity rheumatoid factors are produced by CD5+ B cells from patients with rheumatoid arthritis.J Exp Med1988https://conductscience.org/library/papers/3264319PubMed
1225907284B cells generated by B-1 development can progress to chronic lymphocytic leukemia.Ann N Y Acad Sci2015https://conductscience.org/library/papers/25907284PubMed
132934473Leu-1+ (CD5+) B cells. A major lymphoid subpopulation in human fetal spleen: phenotypic and functional studies.J Immunol1986https://conductscience.org/library/papers/2934473PubMed
1419228640Secondary CD5+ diffuse large B-cell lymphoma not associated with transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter syndrome).Am J Clin Pathol2009https://conductscience.org/library/papers/19228640PubMed
1532694049De Novo CD5+ Diffuse Large B-Cell Lymphoma: Biology, Mechanism, and Treatment Advances.Clin Lymphoma Myeloma Leuk2020https://conductscience.org/library/papers/32694049PubMed
1611751967CD5-negative regulation of B cell receptor signaling pathways originates from tyrosine residue Y429 outside an immunoreceptor tyrosine-based inhibitory motif.J Immunol2002https://conductscience.org/library/papers/11751967PubMed
1711043765Regulation of the phospholipase C-gamma2 pathway in B cells.Immunol Rev2000https://conductscience.org/library/papers/11043765PubMed
1810327049Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1.Oncogene1999https://conductscience.org/library/papers/10327049PubMed
1910903736
Src homology region 2 (SH2) domain-containing phosphatase-1 dephosphorylates B cell linker protein/SH2 domain leukocyte protein of 65 kDa and selectively regulates c-Jun NH2-terminal kinase activation in B cells.
J Immunol2000https://conductscience.org/library/papers/10903736PubMed
2010082557CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1.Mol Cell Biol1999https://conductscience.org/library/papers/10082557PubMed

See all 89 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42266738A study comparing the efficacy of R-CHOP and R-DA-EPOCH regimens in young, high-risk treatment-naïve diffuse large B-cell lymphoma patients: a multicenter retrospective analysis.Am J Cancer Res2026https://conductscience.org/library/papers/42266738PubMed
41443849Efficacy and safety of Pola-R-mini-CHP therapy in patients aged ≥80 years with CD5-positive diffuse large B-Cell lymphoma.J Clin Exp Hematop2026https://conductscience.org/library/papers/41443849PubMed
41088985The EP300-Targeting Drug CCS1477 Inhibits the Growth and Development of Diffuse Large B-Cell Lymphoma by Promoting Apoptosis and Mitophagy to Reduce Drug Resistance.Anticancer Agents Med Chem2026https://conductscience.org/library/papers/41088985PubMed

Download CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39196380

GET https://conductscience.org/api/papers/v1/39196380/references?page=2